Imatinib mesylate in the treatment of unresectable and/or metastatic gastrointestinal stromal tumors / 中国癌症杂志
China Oncology
;
(12)2001.
Artículo
en Chino
| WPRIM
| ID: wpr-675505
ABSTRACT
Purpose:
To evaluate the efficacy and toxicity of imatinib mesylate (STI571) in the treatment of unresectable and/or metastatic gastrointestinal stromal tumors (GIST).Methods:
Ten patients with unresectable and/or metastatic GIST received imatinib at doses of 400 mg qd.Results:
Among 9 evaluable patients, 4 achieved a partial response and 4 had stable disease. Ten patients were evaluable for toxicities. The nonhaematological toxicities included edema (mainly periorbital edema), abdominal pain, diarrhoea, nausea/vomiting, fatigue, intratumoural bleeding, intermittent muscle cramps and conjunctivitis. Myelosuppression was an infrequent side effect.Conclusions:
Imatinib mesylate is an inhibitor of tyrosine kinase and has been proven to be active in patients with unresectable or metastatic GIST. Toxicity is acceptable.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
China Oncology
Año:
2001
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS